Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TN › Knoxville › NPI 1508154915
NP / PA

Keller, Andrew

Keller, Andrew was paid $54K by Medicaid between Jan 2018 and May 2020, across 7 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 58% of everything it billed.

33Billing provider infoKELLER, ANDREW
KNOXVILLE, TN 37934
33aNPI1508154915assigned 07/19/2011
33bProvider typeNurse Practitioner
28Total paid$54K
24GClaims2,935
24DCodes billed7
24AFirst – last monthJan 2018 – May 2020
Compared with peers

Next to other Nurse Practitioner providers in Tennessee

Rank by total paid#71 of 212
Median peer was paid$17K
This provider vs. median3.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$2.0K$4.0K$6.0K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,902$35K
20191,016$18K
202017$382.68
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 58% 1,308 1,172 $31K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 24% 1,015 846 $13K
99203 Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity 14% 267 239 $8K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.2% 222 182 $1K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 79 51 $325.00
80306 <1% 31 30 $116.76
81025 <1% 13 12 $53.64

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.